InvestorsHub Logo
Followers 38
Posts 2285
Boards Moderated 0
Alias Born 12/23/2011

Re: pgh_maulers post# 5875

Thursday, 11/08/2012 10:18:10 AM

Thursday, November 08, 2012 10:18:10 AM

Post# of 130503
Good advice. Just this one piece of news from two days ago says it all about where this company is headed: "Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen."
This is the real thing folks. Divorce yourself from emotion and the message board riff-raff. Know what you own.